Wright Bonilla Quoted on NIH March-In Rights

16 August 2010 BioWorld Insight News
Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BioWorld Insight on August 16, 2010 titled "If NIH Challenges Genzyme’s Patents, Does Anyone Care?" Wright Bonilla discusses a petition filed with the Department of Health and Human Services urging the National Institutes of Health (NIH) to exercises its march-in rights and grant an open license for the use of patents related to Genzyme Corp.’s Fabry disease drug Fabrazyme. She states that it is unlikely that the NIH would pursue an open license for Genzyme’s product because of the complexity of making biologics like Fabrazyme, adding that the agency has in fact never before exercised its march-in rights.

Related Services

Insights

Hatch Comments on DNC-Related Construction Projects in Milwaukee
14 June 2019
Milwaukee Business Journal
Bernard Quoted on Debt-Relief Settlement with ITT Tech Lender
14 June 2019
Wall Street Journal
Dodd and Daughter Profiled in Wisconsin Golf
13 June 2019
Wisconsin Golf
Brinckerhoff Comments on SCOTUS Ruling in Patent Case
11 June 2019
Intellectual Property Magazine
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ
Foley's Government Contracts Annual Update
16 October 2019
Liviona, MI